Evidence map›Paper›PMID 29108325›Full record

ArticleOncotarget2017

Ratio of positive lymph nodes: The prognostic value in stage IV thyroid cancer.

Tingyin Jiang, Chunling Huang, Yuan Xu, Yingrui Su, Guanjie Zhang, Long Xie, Liqun Huang, Shuchun You, Jinshun Zha

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Tingyin JiangDepartment of Nuclear Medicine, Second Affiliated Hospital, Fujian Medicine University, Licheng, Quanzhou 362000, China.
Chunling HuangDepartment of Nuclear Medicine, Second Affiliated Hospital, Fujian Medicine University, Licheng, Quanzhou 362000, China.
Yuan XuCancer Institute, Fudan University Shanghai Cancer Center, Xuhui, Shanghai 200032, China.
Yingrui SuDepartment of Nuclear Medicine, Second Affiliated Hospital, Fujian Medicine University, Licheng, Quanzhou 362000, China.
Guanjie ZhangDepartment of Nuclear Medicine, Second Affiliated Hospital, Fujian Medicine University, Licheng, Quanzhou 362000, China.
Long XieDepartment of Nuclear Medicine, Second Affiliated Hospital, Fujian Medicine University, Licheng, Quanzhou 362000, China.
Liqun HuangDepartment of Nuclear Medicine, Second Affiliated Hospital, Fujian Medicine University, Licheng, Quanzhou 362000, China.
Shuchun YouDepartment of Nuclear Medicine, Second Affiliated Hospital, Fujian Medicine University, Licheng, Quanzhou 362000, China.
Jinshun ZhaDepartment of Nuclear Medicine, Second Affiliated Hospital, Fujian Medicine University, Licheng, Quanzhou 362000, China.
Second Affiliated Hospital of Fujian Medical University · CNFujian Medical University · CNFudan University Shanghai Cancer Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To assess the prognostic value of lymph node ratio (LNR) in patients with stage IV thyroid cancer based on the Surveillance, Epidemiology, and End Results (SEER) database. A total of 4,940 eligible patients were included for the analysis. Kaplan-Meier survival analysis and Cox proportional hazard regression were used to reveal the effect of LNR on overall survival (OS) and disease specific survival (DSS). The optimal cut-off value of LNR for predicting OS and DSS was determined by the time-dependent Receiver Operating Characteristic analysis. By the univariate Cox proportional hazard regression, LNR was significantly associated with OS and DSS in patients with medullary thyroid cancer (MTC), papillary thyroid cancer and anaplastic thyroid cancer (all

Indexed as

lymph node ratiomedullarystage IVsurvivalthyroid cancer

Identifiers

PMID29108325
PMCPMC5668058
OpenAlexW2621662757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.